Advances in Pain Management (Vol. 2, No. 2)

Faculty

Needs Statement

Advances in Pain Management, a CME-accredited educational program, systematically identifies, evaluates, and places into clinical context the most important recent studies into the science and medicine of pain management. It provides rapid access for busy specialists (including pain specialists, anesthesiologists, neurologists, oncologists, general physicians, and primary care physicians) to a critical and clinically relevant review of the developments that will have most impact on their day-to-day practice and is designed to provide management options for clinicians to allow them to better diagnose and treat patients suffering chronic pain.

Each issue of Advances in Pain Management will present carefully constructed leading (review) articles, written by practicing pain specialists, and intended to equip readers with practical knowledge of the area under discussion. These articles are commissioned to support particular educational themes identified by the Editor-in-Chief, Editorial team, and readers. This issue of Advances in Pain Management presents three such leading articles.

Target Audience

This activity is designed to meet the educational needs of multidisciplinary clinicians and healthcare professionals
involved in the care of patients with chronic pain.

Objectives

Objectives: After reading this article the reader should be able to discuss:
1. Screening tools for pain-reducing medication misuse or abuse;
2. Guidelines for monitoring chronic pain patients undergoing opioid therapy;
3. Instruments for assessing the biophychosocial aspects of pain;
4. Recommended treatment selection for substance abusers;
5. The use of opioids for chronic pain;
6. Universal precautions in chronic pain management.

Accreditation

CME
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Kentucky College of Medicine and Remedica Medical Education. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this educational activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Faculty Disclosure

Dr. Gatchel has received research support and/or consultancy fees from the Department of Defense, Endo Pharmaceuticals, the National Institutes of Health, PRIDE Research Foundation and West Coast Spine Restoration Center.

Dr. Sullivan and Dr. Manubay have no financial interests to disclose.

Dr. Comer serves as a consultant to Cephalon Pharmaceuticals, King Pharmaceuticals, and Inflexxion. In addition, she has received funding from Grunenthal GmbH and from Schering-Plough Corporation.

Dr. Weaver has served on the Speaker’s Bureau for PriCara and the Advisory Board for Cephalon, Inc.; has
received consultant fees from Cephalon, Inc., Endo Pharmaceuticals, Javelin Pharmaceuticals, MEDA AB and Purdue Pharma LP.

Activity Sponsorship

This activity is jointly sponsored by the University of Kentucky and Remedica Medical Education. Supported by an unrestricted educational grant from Cephalon.